

Product datasheet for TP721391

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

ADORA2A Human Recombinant Protein, Membrane Nanoparticle

Product data:

Product Type: Recombinant Proteins

Description: Recombinant Human ADORA2A full length protein-Membrane Nanoparticle, 50µg

Species: Human Expression Host: HEK293

Expression cDNA Clone

or AA Sequence:

C-terminal Flag tagged overexpression cDNA clone

Tag: C-term Flag Tag

Predicted MW: The human full length ADORA2A protein has a MW of 44.7 kDa

Concentration: Please refer to the Certificate of Analysis (COA) for the lot-specific concentration before

lyophilization.

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants

before lyophilization.

Reconstitution Method:1. Before opening the tube cap, centrifuge the sample tube at 5000g for 3-5min at room

temperature to ensure the lyophilized sample settles down at the bottom of the tube.

2. Calculate the volume for reconstitution (in μ L) using the formula: [Quantity

(mg)/Concentration (mg/mL)]x1000

3. Dissolve the lyophilized protein sample in sterile water based on the calculated volume (µL)

4. After adding sterile water, cover the lid and mix by gently tapping the tube 5-10 times. Note:

Do not vortex or vigorously pipette the sample.

Storage: Store at -20°C to -80°C for 12 months in lyophilized form.

Stability: After reconstitution, if not intended for use within a month, aliquot and store at -80°C. Avoid

repeated freezing and thawing.

Locus ID: 135

UniProt ID: P29274

Synonyms: A2aR; ADORA2; RDC8

Protein Families: Druggable Genome, GPCR, Transmembrane

Protein Pathways: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle

contraction





Product images:




Figure 2. FACS analysis of ADORA2A MNPs A. Negative Control 1: ADORA2A full length membrane nanoparticles samples were stained only with Goat anti-mouse IgG 488 secondary antibody. B. Negative Control 2: Control membrane nanoparticles samples were stained with anti-ADORA2A antibody (R&D systems, MAB9497R) at 2µg/mL, followed by Goat antimouse IgG 488 secondary antibody. C. Negative Control 3: ADORA2A full length membrane nanoparticles samples were stained with anti-His antibody (an irrelevant antibody) at 2µg/mL, followed by Goat anti-mouse IgG 488 secondary antibody. D. ADORA2A full length membrane nanoparticles samples were stained with anti-ADORA2A antibody (R&D systems, MAB9497R) at 2µg/mL, followed by Goat anti-mouse IgG 488 secondary antibody.

ELISA assay to evaluate ADORA2A-MNPs 0.5µg Human ADORA2A-MNPs per well




Figure 1. Elisa plates were pre-coated with 0.5µg/per well purified human ADORA2A full length membrane nanoparticles. Serial diluted anti-Flag monoclonal antibody solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-Flag monoclonal antibody binding with ADORA2A full length membrane nanoparticles is 6.796ng/ml.